FDA News

Featured Article
Nearly a Million Vials of Chemoprotectant Recalled
Teva Pharmaceuticals USA is recalling nearly a million vials of leucovorin calcium for injection over sterility concerns.
Chemotherapy Drug Recalled
A Class II recall is active for a prescription chemotherapy drug used to treat cancer of the colon or rectum.
Labeling Error Prompts Class I Recall
A Class I recall has been issued for 34,860 single-dose vials of cisatracurium besylate injection from Meitheal Pharmaceuticals Inc.

Newsfeed

Nearly a Million Vials of Chemoprotectant Recalled
Chemotherapy Drug Recalled
Labeling Error Prompts Class I Recall
Chronic Kidney Disease Drug Recalled
Vertigo Tablets Recalled in Two States
Antibiotic Recalled Over Impurity Findings
Anticoagulant Recalled Over Mislabeled Syringes
GERD Injection Recalled
View More

Insights

Reviewing the Recent FDA Approval of Venclexta for AML
Tony Lin, PharmD, senior scientific director, AbbVie US medical affairs, discusses the VIALE-A and VIALE-C trials, which helped determine the approval of Venclexta for acute myeloid leukemia, and highlights what this approval means for clinical…
FDA Requires Stronger Warning Labels for Benzodiazepines
Michael Cawley, PharmD, discusses the recent news from the FDA on benzodiazepines, which includes new boxed warnings for the use of these medications, and changes to the prescribing information and patient medication guides.
Anesthetic Injection Recalled
A Class II recall is active for a prescription analgesic injection used during anesthetic periods, premedication, induction and maintenance, and in the immediate postoperative period.
View More

Interactive Features

CV Deaths, Hospitalizations Reduced for Patients Treated With Farxiga
In this episode of PopHealth Perspectives, Kiersten Combs, vice president, US Cardiovascular and Metabolic Disease (US CVMD) and Naeem Khan, MD, vice president, medical, US CVMD, AstraZeneca, discuss the recent approval of Farxiga (dapagliflozin),…
Positive Results Support Approval of Treatment for Patients With Multiple Myeloma
Saad Usmani, MD, discusses the recent approval of daratumumab subcutaneous formulation for patients with multiple myeloma, and explains the major benefits of this treatment for this patient population.
Breaking Down the Expanded Approval of a CLL Treatment
In this podcast, Andree Amelsberg, vice president of US Medical Affairs Oncology and Hematology at Janssen, and Danelle James, Imbruvica clinical science lead at Pharmacyclics LLC, an AbbVie company, discuss the recent expanded approval of Imbruvica…
Identifying Recent Pain Medication Recalls
Which narcotic pain medication—used to treat moderate to severe pain—has been recalled in the last two FDA Enforcement Reports?
View More
Back to Top